FASEB SRC on Autoimmunity

项目总结 在过去的几年里，我们对本病致病机制的了解有了巨大的增长。 自身免疫，以及对不同免疫之间的相似性和重要区别的新认识 自身免疫性疾病。自身免疫研究的快速发展领域的例子是识别和 新的致病T和B细胞亚群分泌独特的炎症介质和 对遗传易感性、环境压力和微生物组之间的界面的新见解 代谢体。这些发现在很大程度上是由基础科学家的工作产生的，今年夏天 关于自身免疫的会议历来侧重于讨论基础研究的新发现 自身免疫力。然而，我们认为，对于基础科学家来说，建立和保持联系是至关重要的 致那些致力于将机制转化为治疗靶点的科学家。例如，意想不到的 治疗性B细胞去除在一些自身免疫性疾病中的疗效已促使人们加紧研究 基础科学家研究B细胞在致病途径中的作用。以同样的方式，对角色的理解 影响免疫调节的微生物群的研究导致了潜在的 针对其他疾病的新治疗策略，如炎症性肠病和类风湿性关节炎。 关于调节性和效应性T细胞新陈代谢的基本信息激发了人们对推动 代谢操纵作为治疗策略，不仅在癌症中，而且在自身免疫方面也是如此。值得注意的是， 使用检查点抑制剂进行癌症免疫治疗的主要并发症是发展一种广泛的- 一系列自身免疫性并发症。因此，在保持对前沿基础研究的关注的同时， 自身免疫，我们将继续有翻译科学家作为演讲者，专注于自身免疫的机制 在人类自身免疫性疾病中的组织损伤，这将讨论治疗自身免疫的新策略 自身免疫中操纵免疫系统成功和失败的疾病和最新数据 人类和癌症患者。我们预计，对自身免疫性疾病治疗的重视将 吸引基础和行业科学家，并将激发初级和老牌科学家的浓厚兴趣 调查人员。这次会议的规模和背景是促进数据开放交换和交叉访问的理想选择。 将激发自身免疫研究的新假设和新方向的想法的培养。

PROJECT SUMMARY There has been enormous growth in the past few years in our understanding of pathogenic mechanisms in autoimmunity, and a new recognition of the similarities and important distinctions between different autoimmune diseases. Examples of rapidly moving areas of research in autoimmunity are the identification and characterization of new subsets of pathogenic T and B cells that secrete unique inflammatory mediators and novel insights into the interface between genetic susceptibility, environmental stress, and the microbiome and metabolome. These findings have emerged largely from the work of basic scientists, and this FASEB summer conference on Autoimmunity has historically focused on discussion of new findings in basic research in autoimmunity. However, we believe that it is crucial for basic scientists to establish and maintain connections to scientists who are working to translate mechanisms into therapeutic targets. For example, the unexpected efficacy of therapeutic B cell depletion in some autoimmune diseases has prompted intense investigation by basic scientists into the role of B cells in pathogenic pathways. In a like manner, the understanding of the role of the microbiome influencing immune regulation has led to the discussion and development of potentially novel therapeutic strategies for other illnesses, such as inflammatory bowel disease and rheumatoid arthritis. Basic information on metabolism in regulatory and effector T cells has spurred interest in the drive toward metabolic manipulations as therapeutic strategies, not only in cancer, but also in autoimmunity. Notably one of the major complications of cancer immunotherapy with checkpoint inhibitors is the development of a wide- range of autoimmune complications. Therefore, while maintaining a focus on cutting edge basic research in autoimmunity, we will continue to have as speakers translational scientists that focus upon mechanisms of tissue injury in human autoimmune diseases, and that will discuss new strategies for treating autoimmune diseases and current data on the successes and failures of manipulating the immune system in autoimmune humans and cancer patients. We expect that emphasis on therapeutic treatment of autoimmune disease will attract both basic and industry scientists and will stimulate strong interest among both junior and established investigators. The size and setting of this meeting are ideal to promote the open exchange of data and cross- fertilization of ideas that will stimulate new hypotheses and directions in autoimmunity research.